Artículos de revistas sobre el tema "Anti-HER2 therapy"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Anti-HER2 therapy".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Pospíšková, Markéta y Milan Kohoutek. "Breast cancer a chronic disease? The Anti-HER2 therapy". Klinická farmakologie a farmacie 30, n.º 4 (1 de diciembre de 2016): 28–30. http://dx.doi.org/10.36290/far.2016.032.
Texto completoNahleh, Zeina A., Elizabeth B. Elimimian, Leah C. Elson, Brian Hobbs, Wei Wei y Cassann N. Blake. "Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database". Breast Cancer: Basic and Clinical Research 14 (enero de 2020): 117822342094569. http://dx.doi.org/10.1177/1178223420945694.
Texto completoBabar, Tania, Christopher Blomberg, Eileen Hoffner y Xinhua Yan. "Anti-HER2 Cancer Therapy and Cardiotoxicity". Current Pharmaceutical Design 20, n.º 30 (31 de agosto de 2014): 4911–19. http://dx.doi.org/10.2174/1381612820666140604145037.
Texto completoLück, Hans-Joachim, Michael Untch, Christian Jackisch, Christoph Zielinski y Rupert Bartsch. "Optimal Sequencing of Anti-HER2 Therapy". Breast Care 9, n.º 2 (2014): 138. http://dx.doi.org/10.1159/000362300.
Texto completoMartínez-Jañez, Noelia, Ignacio Chacón, Ana de Juan, Luis Cruz-Merino, Sònia del Barco, Isaura Fernández, Paula García-Teijido et al. "Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel". Breast Care 11, n.º 2 (2016): 133–38. http://dx.doi.org/10.1159/000443601.
Texto completoCrespo, James, Hongxia Sun, Jimin Wu, Qingqing Ding, Guilin Tang, Melissa Robinson, Hui Chen, Aysegul A. Sahin y Bora Lim. "HER2 targeted therapy and outcome in HER2-equivocal cases after 2018 ASCO/CAP HER2 guideline modification." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e14729-e14729. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14729.
Texto completoMehta, Sandhya, Jinlin Song, Melissa Pavilack, Jipan Xie, Xiaoyu Nie, Mohini Vembusubramanian y Jackie Kwong. "Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients." Journal of Clinical Oncology 38, n.º 29_suppl (10 de octubre de 2020): 282. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.282.
Texto completoKatayama, Ayaka, Islam M. Miligy, Sho Shiino, Michael S. Toss, Karim Eldib, Sasagu Kurozumi, Cecily M. Quinn et al. "Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer". Modern Pathology 34, n.º 7 (1 de febrero de 2021): 1271–81. http://dx.doi.org/10.1038/s41379-021-00738-5.
Texto completoPetráková, Katarína. "Residual disease after neoadjuvant systemic anti-HER2 therapy: the KATHERINE trial". Onkologie 14, n.º 2 (2 de junio de 2020): 93–95. http://dx.doi.org/10.36290/xon.2020.017.
Texto completoRaghav, Kanwal, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter et al. "Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer". JCO Precision Oncology, n.º 3 (diciembre de 2019): 1–13. http://dx.doi.org/10.1200/po.18.00226.
Texto completovon Minckwitz, G. "138 Anti-HER2 therapy treatment after progression". European Journal of Cancer Supplements 7, n.º 2 (septiembre de 2009): 34–35. http://dx.doi.org/10.1016/s1359-6349(09)70121-1.
Texto completoKillock, David. "Leveraging ADCC to enhance anti-HER2 therapy". Nature Reviews Clinical Oncology 14, n.º 4 (14 de febrero de 2017): 200. http://dx.doi.org/10.1038/nrclinonc.2017.19.
Texto completoIwata, Hiroji. "The perspective of anti-HER2 therapy for HER2 positive breast cancer". Annals of Oncology 26 (noviembre de 2015): vii11. http://dx.doi.org/10.1093/annonc/mdv405.03.
Texto completoOke, Oluchi, Carla L. Warneke, Mariana Chavez-Mac Gregor, Andrea Milbourne y Jennifer Keating Litton. "Outcomes related to delayed initiation of anti-HER 2 therapy in pregnant HER2 positive breast cancer patients." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e12059-e12059. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e12059.
Texto completoChia, Stephen K. "Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease". American Society of Clinical Oncology Educational Book, n.º 35 (mayo de 2015): e41-e48. http://dx.doi.org/10.14694/edbook_am.2015.35.e41.
Texto completoPernas, Sonia y Sara M. Tolaney. "HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance". Therapeutic Advances in Medical Oncology 11 (enero de 2019): 175883591983351. http://dx.doi.org/10.1177/1758835919833519.
Texto completoBick, Gregory, Jasmine Zhang, Elyse E. Lowe y Xiaoting Zhang. "Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance". Cancer Drug Resistance 5, n.º 2 (2022): 498–510. http://dx.doi.org/10.20517/cdr.2022.33.
Texto completoKamada, Yoshihiko, Naoko Takigami, Kanou Uehara, Kentaro Tamaki y Nobumitsu Tamaki. "Survival of stage 4 primary breast cancer cases after surgery by intrinsic subtype: HER2-positive subtype potentially curable." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e13026-e13026. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e13026.
Texto completoRamamoorthi, Ganesan, Krithika Kodumudi, Colin Snyder, Payal Grover, Hongtao Zhang, Mark I. Greene, Amrita Basu et al. "Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma". Journal for ImmunoTherapy of Cancer 10, n.º 6 (junio de 2022): e004841. http://dx.doi.org/10.1136/jitc-2022-004841.
Texto completoCrespo, James, Hongxia Sun, Jimin Wu, Qing-Qing Ding, Guilin Tang, Melissa K. Robinson, Hui Chen, Aysegul A. Sahin y Bora Lim. "Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy". PLOS ONE 15, n.º 11 (12 de noviembre de 2020): e0241775. http://dx.doi.org/10.1371/journal.pone.0241775.
Texto completoLoft, Matthew, Sheau Wen Lok, Richard H. De Boer, Laeeq Malik, Sally Greenberg, Belinda Yeo, Angelyn Anton et al. "Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): 1038. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1038.
Texto completoMahdi, H., M. Hasipek, Y. Guan, D. Grabowski, H. Q. Al-Sudani, Y. Parker, A. Boyd, P. G. Rose, D. Lindner y B. K. Jha. "Dual anti-HER2 therapy in HER2+ uterine and ovarian carcinomas: Durable effect with combined therapy". Gynecologic Oncology 154 (junio de 2019): 85–86. http://dx.doi.org/10.1016/j.ygyno.2019.04.201.
Texto completoAdvani, Pooja P., Jennifer A. Crozier y Edith A. Perez. "HER2 testing and its predictive utility in anti-HER2 breast cancer therapy". Biomarkers in Medicine 9, n.º 1 (enero de 2015): 35–49. http://dx.doi.org/10.2217/bmm.14.95.
Texto completoMacNeil, Ian A., David J. Burns, Benjamin E. Rich, Sajjad M. Soltani, Samantha Kharbush, Nicole G. Osterhaus, Brian F. Sullivan, Douglas M. Hawkins, Jodie R. Pietruska y Lance G. Laing. "New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified". Journal of Cancer Research and Clinical Oncology 146, n.º 3 (8 de febrero de 2020): 605–19. http://dx.doi.org/10.1007/s00432-020-03144-7.
Texto completoGaibar, Maria, Laura Beltrán, Alicia Romero-Lorca, Ana Fernández-Santander y Apolonia Novillo. "Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer". Journal of Oncology 2020 (7 de marzo de 2020): 1–13. http://dx.doi.org/10.1155/2020/6375956.
Texto completoKolyadina, I. V. y I. V. Poddubnaya. "Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy". Tumors of female reproductive system 16, n.º 3 (12 de enero de 2021): 46–56. http://dx.doi.org/10.17650/1994-4098-2020-16-3-46-55.
Texto completoLv, Huimin, Min Yan y Zefei Jiang. "Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer". Therapeutic Advances in Medical Oncology 13 (enero de 2021): 175883592110133. http://dx.doi.org/10.1177/17588359211013326.
Texto completoSawaki, Masataka. "Anti-HER2 Therapy in Elderly Breast Cancer Patients". Reviews on Recent Clinical Trials 9, n.º 4 (6 de marzo de 2015): 263–66. http://dx.doi.org/10.2174/1574887109666141127102035.
Texto completoRefae, Sadal, Barbara Pistilli y Suzette Delaloge. "Extended anti-HER2 therapy in early breast cancer". Current Opinion in Oncology 28, n.º 6 (noviembre de 2016): 469–75. http://dx.doi.org/10.1097/cco.0000000000000325.
Texto completoPondé, Noam F., Matteo Lambertini y Evandro de Azambuja. "Twenty years of anti-HER2 therapy-associated cardiotoxicity". ESMO Open 1, n.º 4 (julio de 2016): e000073. http://dx.doi.org/10.1136/esmoopen-2016-000073.
Texto completoXiao, Xian y Yingjie Jia. "Progress in anti-HER2 targeted therapy of metastatic lung cancer". E3S Web of Conferences 271 (2021): 03074. http://dx.doi.org/10.1051/e3sconf/202127103074.
Texto completoBilani, Nadeem, Marita Yaghi, Diana Saravia, Iktej Jabbal, Maroun Bou Zerdan, Leah Elson, Hong Liang y Zeina Nahleh. "Abstract P2-07-07: Does OncotypeDX have predictive value in HER2+ breast cancer?" Cancer Research 82, n.º 4_Supplement (15 de febrero de 2022): P2–07–07—P2–07–07. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-07-07.
Texto completoNahleh, Zeina A., Brian Hobbs, Elizabeth Elimimian, Wei (Auston) Wei, Annie Gupta y Cassann N. Blake. "Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Database." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): 547. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.547.
Texto completoShen, Xia-Bo, Jia-Yi Wu, Ke-Yu Chen, Zi-Ru Fang, Guang-Liang Li, Wei-Bin Zou, Xiaojia Wang y Xi-Ying Shao. "Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e13023-e13023. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e13023.
Texto completoMoyer, Cassandra L., Abhijit Mazumdar, Jamal Hill, Martin E. Sanders y Powel Brown. "Abstract P4-01-14: The RXR agonist, IRX4204, increases the anti-tumor activity of HER2-targeted therapies in HER2-amplified breast cancer". Cancer Research 82, n.º 4_Supplement (15 de febrero de 2022): P4–01–14—P4–01–14. http://dx.doi.org/10.1158/1538-7445.sabcs21-p4-01-14.
Texto completoEspinosa Fernandez, Jose Rodrigo, Teruo Yamauchi, Chiyo K. Imamura, Hideko Yamauchi, Hiromitsu Jinno, Maiko Takahashi, Yuko Kitagawa et al. "Comprehensive assessment of cancer stem cell like cells in prediction of pathologic complete response to preoperative dual anti–HER2 therapy for HER2–positive primary breast cancer." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e12123-e12123. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e12123.
Texto completoMeisel, Jane Lowe, Vyshak Alva Venur, Michael Gnant y Lisa Carey. "Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began". American Society of Clinical Oncology Educational Book, n.º 38 (mayo de 2018): 78–86. http://dx.doi.org/10.1200/edbk_201037.
Texto completoZhu, X. y S. Verma. "Targeted therapy in her2-positive metastatic breast cancer: a review of the literature". Current Oncology 22 (15 de enero de 2015): 19. http://dx.doi.org/10.3747/co.22.2363.
Texto completoYang, Jixin, Yuqing Yang, Xinxin Wen, Jiang Wu, Jing Yu, Lei Wang, Meiling Huang, Wenyu Hu, Wen Ma y Nanlin Li. "Neoadjuvant pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by nab-paclitaxel (Nab-P) as primary chemotherapy continuously combined with dual HER2 blockage for HER2-positive breast cancer: A single-arm phase 2 trial (Brecan Trial)." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e12622-e12622. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e12622.
Texto completoSarode, Venetia, Tricia Rood, Yulun Liu, Yisheng Fang, Sunati Sahoo, Yan Peng, Helena Hwang, Marilyn Leitch y Barbara Haley. "Abstract P1-02-14: A comparative analysis of clinical and pathologic characteristics of patients with HER2 positive breast cancer treated with neoadjuvant versus adjuvant anti-HER2 therapy: Analysis of 397 cases". Cancer Research 82, n.º 4_Supplement (15 de febrero de 2022): P1–02–14—P1–02–14. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-02-14.
Texto completoGoldner, Marcelle, Maria A. Franzoi, Lissandra D. Lago y Noam Pondé. "Anti-HER2 therapy for breast cancer in older patients". Future Oncology 16, n.º 19 (julio de 2020): 1393–407. http://dx.doi.org/10.2217/fon-2020-0036.
Texto completoJohnson, Kai Conrad Cecil, Ai Ni, Michael Grimm, Sagar D. Sardesai, Daniel G. Stover, Mathew Amprayil Cherian, Margaret Elena Gatti-Mays et al. "The survival benefit of anti-HER2 treatment in the management of small (T1mic, T1a, T1b, T1c), node-negative HER2+ breast cancer." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): 532. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.532.
Texto completoJeong, Hwa Yeon, Hyeri Kim, Myunghwa Lee, Jinju Hong, Joo Han Lee, Jeonghyeon Kim, Moon Jung Choi, Yong Serk Park y Sung-Chun Kim. "Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy". International Journal of Molecular Sciences 21, n.º 24 (21 de diciembre de 2020): 9764. http://dx.doi.org/10.3390/ijms21249764.
Texto completoWatanabe, Kenichi, Kanako Hagio, Motoi Baba, Mayuko Ikarashi, Masako Sato, Nobumoto Tomioka y Masato Takahashi. "Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes". Annals of Oncology 26 (noviembre de 2015): vii143. http://dx.doi.org/10.1093/annonc/mdv472.166.
Texto completoRoss, J. S. "Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy". Drug News & Perspectives 22, n.º 2 (2009): 93. http://dx.doi.org/10.1358/dnp.2009.22.2.1334452.
Texto completoMasuda, Takahito, Hiroshi Fujimoto, Ryotaro Teranaka, Masayuki Kuroda, Yasuyuki Aoyagi, Takeshi Nagashima, Takafumi Sangai et al. "Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer". Breast Cancer Research and Treatment 180, n.º 3 (2 de marzo de 2020): 625–34. http://dx.doi.org/10.1007/s10549-020-05581-x.
Texto completoZhang, Jingwei, Adam J. Pearson, Nitin Sabherwal, Brian A. Telfer, Nisha Ali, Karmern Kan, Qiuping Xu et al. "Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1–S Cell-Cycle Transition". Cancer Research Communications 2, n.º 3 (marzo de 2022): 131–45. http://dx.doi.org/10.1158/2767-9764.crc-21-0089.
Texto completoChoi, Jae Hyeog, Ki Hyang Kim, Kug Hwan Roh, Hana Jung, Su Kil Seo, Il Whan Choi, Sung Su Yea y SaeGwang Park. "Combination therapy of a PI3K p110α-isoform-selective inhibitor and anti-HER2/neu antibody enhances the anti-tumor immunity in breast cancer mouse model". Journal of Immunology 198, n.º 1_Supplement (1 de mayo de 2017): 204.9. http://dx.doi.org/10.4049/jimmunol.198.supp.204.9.
Texto completoGámez-Chiachio, Manuel, Carmen Ramos-Nebot, Ángela Molina-Crespo, Pérez-Torres Bárbara, Lidia Martínez, David Sarrió y Gema Moreno- Bueno. "Gasdermin B over-expression modulates HER2-targeted therapy resistance through LC3B/Rab7 interaction". IBJ Plus 1, s5 (3 de junio de 2022): 23. http://dx.doi.org/10.24217/2531-0151.22v1s5.00023.
Texto completoGuiu, S., M. A. Mouret Reynier, M. Toure y B. Coudert. "Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy". Journal of Oncology 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/854121.
Texto completo